Bivalirudin (Bivalirudin) Patent Expiration, LOE Window & CMS Spending

Bivalirudin (Bivalirudin) by Multi-Source Generic Manufacturers: Multi-Source Generic Molecule, 14 AB generics, $3.1M 2024 CMS Part D & Medicaid spend, and $900 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorMulti-Source Generic Manufacturers
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors14
2024 CMS Total Public Spend$3.1M
2024 Medicare Part D Spend$0
2024 Medicaid Spend$3.1M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($900 intro WAC)